DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Biogen’s AMD Biosimilar Gets Approval; SmartLabs Series B Funding; BARDA, Partner Therapeutics in Sepsis Space; Synlogic to Explore Sepsis Market Domain Visit Post
2 FDA’s New Drug Application to ALS Drug; Approval to BeiGene’s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises Visit Post
3 Duchenne Muscular Dystrophy Market: What's More Beyond Exon-Skipping Therapies? Visit Post
4 New Approaches and Evolutions to Reshape the Diabetes Management and Care Visit Post
5 LQTT secures $19M; Nanox acquires Zebra Medical Vision; Takeda leads IBD drug; Visus raises $20M Visit Post
6 Nevro's Spinal Cord Stimulation; Boston's PINNACLE FLX; NuVasive's Modulus ALIF; J&J's VERITAS Vision System; Medtronic's DCB Catheter; AngelMed's Heart Attack Warning System Visit Post
7 Unity's advanced vascular eye disease trial; Rallybio raises $100 M; Sanofi bets over $1B for Eureka's candidate; Lilly invests in MiNA; Visit Post
8 How will Pharmacotherapies help the growing number of Presbyopes? Visit Post
9 Age-related Hearing Loss Device Market Dynamics Expected to Step into Growth Quadrant Visit Post
10 How Pharmaceutical Companies Are Mitigating The Gap In The Eye Disorders Treatment Market Visit Post
11 MedTech Industry Roars Back as FDA Approvals Soar Visit Post
12 Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval Visit Post
13 Increasing Prevalence and Upcoming Novel Therapeutic Approaches: What is Shaping the Hepatitis D Market Outlook? Visit Post
14 8 Of The Most Common Foods Allergies - Do You Have One? Visit Post
15 Roche's quantitative COVID-19 antibody test; Janssen buys a gene therapy asset; Zimmer Acquires A&E Medical; Glaucoma research study: Merck chooses TriNKET cancer immunotherapy program; Ovid fails Angelman phase 3 study Visit Post
16 Top Emerging Therapies To Watch Out for in the Retinal Vein Occlusion Market Visit Post
17 What are the options available for the treatment of Retinal vein occlusion? Visit Post
18 Keratoconus - Rare? Not really! Visit Post
19 An Eye-Blinding Scenario of Vernal keratoconjunctivitis Visit Post
20 Mapping The Pipeline Development In The Geographic Atrophy Market Visit Post
21 One of the leading causes of blindness, and a sight-threatening disease, Uveitis, now has novel treatment approaches in its pipeline Visit Post
22 What is driving Retinitis pigmentosa market forward? Visit Post
23 Retinitis Pigmentosa: A complex disease, and the increasing gap between prevalence and diagnosed prevalence Visit Post
24 Promising therapies that might shift Wet Age-related Macular Degeneration Market in the next decade Visit Post
25 Wet Age-Related Macular Degeneration: Unravelling the complex disease with comprehensive R&D Visit Post
26 Thyroid awareness month Visit Post
27 Thyroid eye disease market: New therapies enter the TED market Visit Post
28 Cumberland’s methotrexate product gets approval in the US; Baker Brothers purchases stake in Kodiak’s KSI-301; Sanofi offloads Seprafilm unit to Baxter Visit Post
29 Geographic Atrophy Treatment Market: Novel Therapies to Enter the Market Visit Post
30 Boehringer Ingelheim ties up with Inflammasome Therapeutics Visit Post
31 Daiichi Sankyo fuels commercialization of DS-8201 in Japan; Roivant Sciences transfers its biotech stake for USD 3 Billion; FDA, EMA accepts marketing of Allergan’s abicipar Visit Post
32 Vertex acquires Semma; Luxturna gets approval for rare eye disorder Visit Post
33 Allergic Conjunctivitis Therapy Market and Pipeline Analysis Visit Post
34 Leber Hereditary Optic Neuropathy Treatment Market Visit Post
35 Cataract Awareness Month Visit Post
36 AstraZeneca-Daiichi’s results; Novartis remunerates; Pfizer to acquire Therachon; Gilead & Goldfinch Bio collaboration Visit Post
37 Japan has got new ways to treat corneas Visit Post
38 World Glaucoma Week Visit Post
39 Notizia Visit Post
40 Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways Visit Post
41 Notizia Visit Post
42 Notizia Visit Post
43 Ceribell raises $35M; Lyra reels $29.5M; Minoryx raises Euro21M; Alexion acquired Syntimmune Visit Post
44 Atreca secured $125M; OncoResponse bags $40M; Kodiak Sciences’s IPO; Biodesy contemplates $20M Visit Post
45 Commercial Visit Post
46 Commercial Outcomes - Novartis Visit Post
47 Allergic Conjunctivitis (AC)- Market Insights, Epidemiology and Market Forecast- 2027 Visit Post
48 Allergic Conjunctivitis (AC) – Common disorder with increasing prevalence Visit Post
49 Business Cocktail Visit Post
50 Retinal Degeneration : The Current Pipeline Scenario Visit Post
51 Snippet Visit Post
52 Wet AMD: A chronic eye condition with promising therapies Visit Post
53 Medical tourism in India Visit Post
54 Clinigen and Eisai team up; Sanofi, Lonza enter; Fidia to acquire; J&J completes acquisition Visit Post
55 Prosecutors rope Pfizer; Pharma groups to FDA; Regeneron simulates; Otsuka & Lundbeck revive;Philidor execs plead Visit Post
56 PMV Raises; Argos Shares Plummet; Cidara Flunks in; Sarepta Sells to Gilead; Novartis and NHS Ayrshire & Arran launch Visit Post
57 USFDA warns; Vit B3 prevents glaucoma; Zydus Cadila receives nod; U.S. experts soften on DNA editing Visit Post
58 U.K. weighs drug rationing; Applying Digital; FDA slaps Florida Visit Post
59 Anterior Uveitis: A Vision-threatening condition Visit Post
60 Novartis eyes; Pfizer considers cashing; Mylan pushes to seal $465M; Valeant with Takeda for deal Visit Post
61 Bayer Partners with DelSiTech to Develop; Amgen and Arrowhead Announce; Allergan, AstraZeneca’s deal; Lexicon Pharma announces deal Visit Post
62 DelveInsight’s Ophthalmologic disorders based Gene Therapy Reports Visit Post